AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24413351 — intervention group
Group type: EXPERIMENTAL
Intervention: Unrecognised Obstructive Sleep Apnoea (OSA)
Number of subjects: 1200
Study 24414130 — intervention group
Group type: EXPERIMENTAL
Intervention: Local determination of HER2 receptor status
Number of subjects: 196
Study 24414130 — intervention group
Group type: COMPARATOR
Intervention: Central determination of HER2 receptor status
Number of subjects: 196
Study 24414130 — intervention group
Group type: EXPERIMENTAL
Intervention: Local determination of ER receptor status
Number of subjects: 196
Study 24414130 — intervention group
Group type: COMPARATOR
Intervention: Central determination of ER receptor status
Number of subjects: 196
Study 24414130 — intervention group
Group type: EXPERIMENTAL
Intervention: Local determination of PR receptor status
Number of subjects: 196
Study 24414130 — intervention group
Group type: COMPARATOR
Intervention: Central determination of PR receptor status
Number of subjects: 196
Study 24414130 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment plan alteration based on receptor status change
Number of subjects: 196
Study 24415536 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy (protocol I, 3 polychemotherapy blocks, delayed intensification, cranial radiotherapy, and maintenance for 2 years)
Number of subjects: 312
Study 24415536 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy only
Number of subjects: 312
Study 24415536 — intervention group
Group type: COMPARATOR
Intervention: Hematopoietic stem cell transplantation (HSCT)
Number of subjects: 312
Study 24415536 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy for patients with only prednisone poor response (PPR)
Number of subjects: 312
Study 24415536 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy for MRD-HR patients
Number of subjects: 312
Study 24415536 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy for patients with no CR at day 33
Number of subjects: 312
Study 24415536 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy for patients with t(4;11) translocation
Number of subjects: 312
Study 24415560 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral clofarabine (1 mg to 6 mg daily for 14 or 21 days of a 28-day cycle, for up to five cycles)
Number of subjects: 22
Study 24416138 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib (200 mg/day)
Number of subjects: 12
Study 24416138 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib (400 mg/day)
Number of subjects: 12
Study 24416138 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib (800 mg/day)
Number of subjects: 12
Study 24416138 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine (300 mg/m2 i.v. weekly ×5 weeks) with radiation therapy (45 Gy in 25 fractions)
Number of subjects: 12
Study 24416138 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 12
Study 24416945 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic prescribing (e-prescribing) using a commercial EHR with clinical decision support
Number of subjects: 20
Study 24416945 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned, but implied as traditional prescribing methods prior to e-prescribing)
Number of subjects: 20
Study 24417450 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampicin-resistant (RIF-R) mutations in Mycobacterium tuberculosis
Number of subjects: 0
Study 24417450 — intervention group
Group type: EXPERIMENTAL
Intervention: Compensatory mutations in the β' subunit of RNA polymerase
Number of subjects: 0
Study 24417450 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrient poor growth conditions
Number of subjects: 0
Study 24417980 — intervention group
Group type: COMPARATOR
Intervention: CTRP-3 concentrations in patients with ACS or SAP
Number of subjects: 362
Study 24417980 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of CTRP-3 levels
Number of subjects: 362
Study 24417980 — intervention group
Group type: EXPERIMENTAL
Intervention: Odds ratio for CAD risk in relation to CTRP-3 levels
Number of subjects: 362
Study 24417980 — intervention group
Group type: COMPARATOR
Intervention: Progranulin levels
Number of subjects: 362
Study 24418731 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical management of pump thrombus
Number of subjects: 382
Study 24418731 — intervention group
Group type: EXPERIMENTAL
Intervention: Pump exchange
Number of subjects: 382
Study 24418731 — intervention group
Group type: EXPERIMENTAL
Intervention: Urgent transplantation
Number of subjects: 382
Study 24418731 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical therapy for pump thrombus
Number of subjects: 382
Study 24418731 — intervention group
Group type: EXPERIMENTAL
Intervention: Survival at 1 year
Number of subjects: 382
Study 24419411 — intervention group
Group type: EXPERIMENTAL
Intervention: EGFR mutation positive
Number of subjects: 1482
Study 24419411 — intervention group
Group type: EXPERIMENTAL
Intervention: EGFR mutation negative
Number of subjects: 1482
Study 24419411 — intervention group
Group type: EXPERIMENTAL
Intervention: Demographic and clinical subgroup analysis
Number of subjects: 1482
Study 24419411 — intervention group
Group type: EXPERIMENTAL
Intervention: Statistical significance of factors
Number of subjects: 1482
Study 24419411 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariate analysis
Number of subjects: 1482
Study 24420643 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriparatide (PTH 1-34) 20 mcg sc daily for 24 months
Number of subjects: 23
Study 24420806 — intervention group
Group type: EXPERIMENTAL
Intervention: CSH intervention schools
Number of subjects: 1157
Study 24420806 — intervention group
Group type: COMPARATOR
Intervention: Comparison schools
Number of subjects: 1157
Study 24422672 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination targeted therapy consisting of sorafenib, temsirolimus, and bevacizumab
Number of subjects: 1
Study 24422782 — intervention group
Group type: EXPERIMENTAL
Intervention: IMRT of the pelvic lymph nodes (51.0 Gy) with a simultaneous integrated boost to the prostate bed (68.0 Gy) in 34 fractions
Number of subjects: 40
Study 24423017 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine long-acting injection (LAI)
Number of subjects: 1752
Study 24423045 — intervention group
Group type: EXPERIMENTAL
Intervention: 2:1 formulation of follitropin alfa and lutropin alfa
Number of subjects: 2220
Study 24423045 — intervention group
Group type: EXPERIMENTAL
Intervention: IVF
Number of subjects: 2220
Study 24423045 — intervention group
Group type: EXPERIMENTAL
Intervention: ICSI/IVF + ICSI
Number of subjects: 2220
Study 24423152 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapidly reversible, sedation-related delirium
Number of subjects: 102
Study 24423152 — intervention group
Group type: EXPERIMENTAL
Intervention: No delirium
Number of subjects: 102
Study 24423152 — intervention group
Group type: COMPARATOR
Intervention: Persistent delirium
Number of subjects: 102
Study 24423285 — intervention group
Group type: EXPERIMENTAL
Intervention: LCI699 (4 mg/d, escalated to 10, 20, 40, and 100 mg/d as needed)
Number of subjects: 12
Study 24423301 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanreotide Autogel 120 mg administered sc every 28 days
Number of subjects: 90
Study 24423462 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose intensity-modulated radiation therapy preceded or not by radical prostatectomy, concurrent intensified-dose docetaxel-based chemotherapy and long-term androgen deprivation therapy
Number of subjects: 35
Study 24423476 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone infusion (4 mg/mL) via adventitial microinfusion catheter
Number of subjects: 20
Study 24423476 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone infusion
Number of subjects: 20
Study 24423745 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole body hydroxyproline production (Wb OH-PRO) assessed by stable isotope 2-D-OH-PRO for 3 hours
Number of subjects: 15
Study 24423745 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma OH-PRO concentrations
Number of subjects: 15
Study 24423745 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of Wb OH-PRO production with plasma OH-PRO concentrations in CF
Number of subjects: 15
Study 24423745 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone mineral density (BMD) in hip
Number of subjects: 15
Study 24423745 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone mineral density (BMD) in spine
Number of subjects: 15
Study 24423745 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole body BMD, lung function, and body composition
Number of subjects: 15
Study 24427455 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugammadex 2.0 mg/kg
Number of subjects: 118
Study 24427455 — intervention group
Group type: COMPARATOR
Intervention: Neostigmine 50 µg/kg with glycopyrrolate 10 µg/kg
Number of subjects: 118
Study 24427766 — intervention group
Group type: EXPERIMENTAL
Intervention: MMRV
Number of subjects: 474
Study 24427766 — intervention group
Group type: COMPARATOR
Intervention: MMR+V
Number of subjects: 474
Study 24428625 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG-asparaginase (1000 iu/m2/dose, intramuscular, 8 or 15 doses at 2-6 weeks intervals, total exposure 30 weeks)
Number of subjects: 786
Study 24428625 — intervention group
Group type: EXPERIMENTAL
Intervention: Re-exposure to PEG-asparaginase in AAP patients
Number of subjects: 786
Study 24428859 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-allergen OIT (peanut)
Number of subjects: 40
Study 24428859 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple food OIT (up to 5 foods)
Number of subjects: 40
Study 24428859 — intervention group
Group type: COMPARATOR
Intervention: Multiple food OIT
Number of subjects: 40
Study 24428877 — intervention group
Group type: COMPARATOR
Intervention: Flow-mediated dilation (FMD) in diabetic patients (median 0.61% (upper limits of first and third quartiles -1.22;3.2))
Number of subjects: 118
Study 24428877 — intervention group
Group type: COMPARATOR
Intervention: Flow-mediated dilation (FMD) in diabetic patients with silent myocardial ischemia (SMI)
Number of subjects: 118
Study 24428877 — intervention group
Group type: COMPARATOR
Intervention: Paradoxical vasoconstriction in diabetic patients with SMI
Number of subjects: 118
Study 24428877 — intervention group
Group type: COMPARATOR
Intervention: Flow-mediated dilation (FMD) in diabetic patients with coronary artery disease (CAD)
Number of subjects: 118
Study 24428877 — intervention group
Group type: COMPARATOR
Intervention: Paradoxical vasoconstriction in diabetic patients with CAD
Number of subjects: 118
Study 24428877 — intervention group
Group type: EXPERIMENTAL
Intervention: Paradoxical vasoconstriction as a predictor for SMI
Number of subjects: 118
Study 24428877 — intervention group
Group type: EXPERIMENTAL
Intervention: Paradoxical vasoconstriction as a predictor for CAD
Number of subjects: 118
Study 24428877 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative predictive value of paradoxical vasoconstriction to detect CAD
Number of subjects: 118
Study 24428927 — intervention group
Group type: EXPERIMENTAL
Intervention: Red cell distribution width (RDW) at cut-off of 18%
Number of subjects: 2091
Study 24428927 — intervention group
Group type: EXPERIMENTAL
Intervention: Red cell distribution width (RDW) at cut-off of 16.4%
Number of subjects: 2091
Study 24428927 — intervention group
Group type: EXPERIMENTAL
Intervention: Red cell distribution width (RDW) at cut-off of 21%
Number of subjects: 2091
Study 24428927 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of hemoglobin ≤ 10 g/dL and RDW >15%
Number of subjects: 2091
Study 24428927 — intervention group
Group type: EXPERIMENTAL
Intervention: Area under the curve for RDW
Number of subjects: 2091
Study 24429069 — intervention group
Group type: EXPERIMENTAL
Intervention: Live oral Salmonella enterica serovar Typhi vaccine Ty21a
Number of subjects: 0
Study 24429069 — intervention group
Group type: COMPARATOR
Intervention: Live oral S. Typhi vaccine CVD 909
Number of subjects: 0
Study 24429093 — intervention group
Group type: EXPERIMENTAL
Intervention: CT lung density measurement
Number of subjects: 1928
Study 24429093 — intervention group
Group type: EXPERIMENTAL
Intervention: Current smoking status
Number of subjects: 1928
Study 24429093 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender (female)
Number of subjects: 1928
Study 24429093 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating biomarkers (SP-D and sRAGE)
Number of subjects: 1928
Study 24429274 — intervention group
Group type: EXPERIMENTAL
Intervention: Spirometry
Number of subjects: 979
Study 24429274 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung volume measurement
Number of subjects: 979
Study 24429274 — intervention group
Group type: EXPERIMENTAL
Intervention: Airway resistance test
Number of subjects: 979
Study 24429274 — intervention group
Group type: EXPERIMENTAL
Intervention: Diffusing capacity measurement
Number of subjects: 979
Study 24429274 — intervention group
Group type: EXPERIMENTAL
Intervention: All tests combined
Number of subjects: 979
Study 24429311 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampicin (RMP)
Number of subjects: 110
Study 24429311 — intervention group
Group type: EXPERIMENTAL
Intervention: Day 7 total RMP level (cut-off 12.50 mg/l)
Number of subjects: 110
Study 24429336 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide 15 mg/day (days 1-14), bortezomib 1.0 mg/m² (days 1, 4, 8, and 11), dexamethasone 40/20 mg/day (cycles 1-4) and 20/10 mg/day (cycles 5-8)
Number of subjects: 64
Study 24429337 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor
Number of subjects: 0
Study 24429337 — intervention group
Group type: EXPERIMENTAL
Intervention: CD34(+) hematopoietic progenitor cells (HPCs) mobilization
Number of subjects: 0
Study 24429337 — intervention group
Group type: EXPERIMENTAL
Intervention: Globin lentiviral vector (TNS9.3.55)
Number of subjects: 0
Study 24429337 — intervention group
Group type: EXPERIMENTAL
Intervention: Vector-encoded β-chain expression
Number of subjects: 0
Study 24429337 — intervention group
Group type: EXPERIMENTAL
Intervention: Stable vector copy number
Number of subjects: 0
Study 24429497 — intervention group
Group type: EXPERIMENTAL
Intervention: Carfilzomib (escalated from 20 to 45 mg/m² on days 1, 2, 8, 9, 15, and 16 of a 28-day cycle)
Number of subjects: 37
Study 24429497 — intervention group
Group type: EXPERIMENTAL
Intervention: Carfilzomib (45 mg/m²), ascorbic acid (1000 mg), and cyclophosphamide (2.2 mg/kg)
Number of subjects: 37
Study 24429497 — intervention group
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Number of subjects: 37
Study 24430093 — intervention group
Group type: EXPERIMENTAL
Intervention: PCOS
Number of subjects: 85
Study 24430093 — intervention group
Group type: EXPERIMENTAL
Intervention: GDF-15
Number of subjects: 85
Study 24430093 — intervention group
Group type: EXPERIMENTAL
Intervention: GDF-9
Number of subjects: 85
Study 24430093 — intervention group
Group type: COMPARATOR
Intervention: PCOS, IH, and healthy controls
Number of subjects: 85
Study 24431228 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofatumumab (OFA) therapy
Number of subjects: 25
Study 24431279 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic sinus surgery (ESS) for patients with comorbid migraine (n = 46)
Number of subjects: 229
Study 24431279 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic sinus surgery (ESS) for patients without comorbid migraine (n = 183)
Number of subjects: 229
Study 24431907 — intervention group
Group type: EXPERIMENTAL
Intervention: Empirical antifungal therapy with itraconazole
Number of subjects: 391
Study 24431909 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous erythropoietin receptor activator (CERA) administered intravenously once every 2 weeks (n=39)
Number of subjects: 80
Study 24431909 — intervention group
Group type: COMPARATOR
Intervention: Epoetin beta administered thrice-weekly (n=41)
Number of subjects: 80
Study 24431909 — intervention group
Group type: EXPERIMENTAL
Intervention: CERA
Number of subjects: 80
Study 24431909 — intervention group
Group type: COMPARATOR
Intervention: Epoetin beta
Number of subjects: 80
Study 24432743 — intervention group
Group type: EXPERIMENTAL
Intervention: Blueberry juice (250 mL)
Number of subjects: 17
Study 24432743 — intervention group
Group type: EXPERIMENTAL
Intervention: Anthocyanin metabolites
Number of subjects: 17
Study 24433194 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin mass drug administration (three annual treatments)
Number of subjects: 3646
Study 24433194 — intervention group
Group type: COMPARATOR
Intervention: Baseline-only treatment
Number of subjects: 3646
Study 24433194 — intervention group
Group type: COMPARATOR
Intervention: Untreated children
Number of subjects: 3646
Study 24433481 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal UCP I/(I + III) ratio before MTX infusion (P1)
Number of subjects: 81
Study 24433481 — intervention group
Group type: EXPERIMENTAL
Intervention: UCP I/(I + III) ratio at the end of MTX infusion (P2)
Number of subjects: 81
Study 24433481 — intervention group
Group type: EXPERIMENTAL
Intervention: UCP I/(I + III) ratio on the day of hospital discharge (P3)
Number of subjects: 81
Study 24433481 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in UCP I/(I + III) ratio between P1 and P3
Number of subjects: 81
Study 24433481 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal UCP I/(I + III) ratio
Number of subjects: 81
Study 24433710 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative remodeling lesions (RI <0.88)
Number of subjects: 697
Study 24433710 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive remodeling lesions (RI >1.00)
Number of subjects: 697
Study 24433710 — intervention group
Group type: COMPARATOR
Intervention: Intermediate remodeling lesions (RI 0.88 to 1.00)
Number of subjects: 697
Study 24434094 — intervention group
Group type: EXPERIMENTAL
Intervention: Customized adherence enhancement plus long-acting injectable antipsychotic (haloperidol decanoate) for 6 months
Number of subjects: 30
Study 24434370 — intervention group
Group type: EXPERIMENTAL
Intervention: mtDRV/rtv (800/100 mg every 24 h)
Number of subjects: 150
Study 24435003 — intervention group
Group type: EXPERIMENTAL
Intervention: Platinum-based chemotherapy
Number of subjects: 313
Study 24435018 — intervention group
Group type: EXPERIMENTAL
Intervention: Infratentorial stroke patients
Number of subjects: 28
Study 24435018 — intervention group
Group type: COMPARATOR
Intervention: Supratentorial stroke patients
Number of subjects: 28
Study 24435018 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 28
Study 24435467 — intervention group
Group type: EXPERIMENTAL
Intervention: Evening primrose oil (EPO) 4-6 g daily for 12 weeks
Number of subjects: 21
Study 24436111 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive battery including memory and learning, psychomotor speed, attention, and executive function scores in RDP patients
Number of subjects: 58
Study 24436111 — intervention group
Group type: EXPERIMENTAL
Intervention: Burke-Fahn-Marsden Dystonia Rating Scale (BFMDRS)
Number of subjects: 58
Study 24436111 — intervention group
Group type: EXPERIMENTAL
Intervention: Unified Parkinson's Disease Rating Scale (UPDRS) motor subscore
Number of subjects: 58
Study 24436111 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive battery scores controlling for psychomotor speed and severity of depressive symptoms
Number of subjects: 58
Study 24438153 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium phosphate (CaP) - additional 1 g calcium/d
Number of subjects: 60
Study 24438153 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D₃ - additional 10 μg/d
Number of subjects: 60
Study 24438153 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium phosphate (CaP) + Vitamin D₃
Number of subjects: 60
Study 24438153 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 24438203 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-administered icatibant (30-mg subcutaneous injection)
Number of subjects: 151
Study 24438203 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-administration of icatibant
Number of subjects: 151
Study 24438203 — intervention group
Group type: COMPARATOR
Intervention: Control group (HCP administered icatibant prior to self-administration)
Number of subjects: 151
Study 24438342 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored support intervention by a diabetes nurse (home visits at 3 weeks, 2 weeks, and 2 months after discharge)
Number of subjects: 200
Study 24438342 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored support intervention by a diabetes nurse
Number of subjects: 200
Study 24438342 — intervention group
Group type: COMPARATOR
Intervention: Consultation by telephone (control group)
Number of subjects: 200
Study 24439297 — intervention group
Group type: EXPERIMENTAL
Intervention: AAV.REP1 (0·6-1·0×10(10) genome particles, subfoveal injection)
Number of subjects: 6
Study 24439297 — intervention group
Group type: COMPARATOR
Intervention: Control eyes (not specified treatment)
Number of subjects: 6
Study 24439931 — intervention group
Group type: EXPERIMENTAL
Intervention: Cixutumumab (20 mg/kg) administered intravenously every 3 weeks until disease progression or intolerable toxic effects
Number of subjects: 49
Study 24439950 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequency of marijuana use
Number of subjects: 332
Study 24439950 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequency of alcohol use
Number of subjects: 332
Study 24439950 — intervention group
Group type: EXPERIMENTAL
Intervention: Interaction of marijuana by alcohol use frequency
Number of subjects: 332
Study 24440085 — intervention group
Group type: EXPERIMENTAL
Intervention: LY2584702 75 mg BID
Number of subjects: 34
Study 24440085 — intervention group
Group type: EXPERIMENTAL
Intervention: LY2584702 100 mg QD
Number of subjects: 34
Study 24440085 — intervention group
Group type: EXPERIMENTAL
Intervention: LY2584702 (various doses)
Number of subjects: 34
Study 24440112 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-dose PCV7
Number of subjects: 221
Study 24440112 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-dose PCV7
Number of subjects: 221
Study 24440112 — intervention group
Group type: COMPARATOR
Intervention: PPV23
Number of subjects: 221
Study 24440279 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib 400mg twice daily continuously until disease progression or intolerable toxicity
Number of subjects: 64
Study 24440330 — intervention group
Group type: EXPERIMENTAL
Intervention: Amigo Remote Catheter System (RCS)
Number of subjects: 50
Study 24440330 — intervention group
Group type: COMPARATOR
Intervention: Manual ablation
Number of subjects: 50
Study 24440471 — intervention group
Group type: EXPERIMENTAL
Intervention: Community based model for cervical cancer screening using self-sampling
Number of subjects: 8382